Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats

Experimental Physiology

Volumn 94, Issue 9, 2009, Pages 1016-1023

  Nagai, Yukiko ^a   Ichihara, Atsuhiro ^b   Nakano, Daisuke ^c   Kimura, Shoji ^c   Pelisch, Nicolas ^a   Fujisawa, Yoshihide ^a   Hitomi, Hirofumi ^c   Hosomi, Naohisa ^a   Kiyomoto, Hideyasu ^a   Kohno, Masakazu ^a   Ito, Hiroshi ^b   Nishiyama, Akira ^c  

^a KAGAWA UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; FRUCTOSE; GLUCOSE; INSULIN; PRORENIN; TRIACYLGLYCEROL;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NONHUMAN; RAT; SOLEUS MUSCLE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOCYTES; ADIPONECTIN; ANGIOTENSIN II; ANIMALS; BASE SEQUENCE; BLOOD GLUCOSE; BLOOD PRESSURE; CELL SIZE; CHOLESTEROL; DIETARY CARBOHYDRATES; ENZYME ACTIVATION; FATTY ACIDS, NONESTERIFIED; FRUCTOSE; INSULIN; INSULIN RESISTANCE; MALE; MUSCLE, SKELETAL; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; RENIN; RNA, MESSENGER; TRIGLYCERIDES;

EID: 68949111857     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2009.048108     Document Type: Article

References (27)

1. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI & Kahn BB (2001). Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409, 729 733.
2. Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G & Grino M (2007). Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 292, R274 R282.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981 2997.
4. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S & Wedel H (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995 1003.
5. Fan YY, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, Sun GP, Kohno M, Fujita M, Abe Y & Nishiyama A (2006). Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res 29, 169 178.
6. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC & Muller DN (2008). Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51, 682 688.
7. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO & Bjorck JE (1999). Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353, 611 616.
8. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK & Krekler M (2001). Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38, 884 890.
9. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T & Saruta T (2004). Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114, 1128 1135.
10. Ichihara A, Kaneshiro Y & Suzuki F (2006a). Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension. Expert Opin Investig Drugs 15, 1137 1139.
11. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Nakagawa T, Nishiyama A, Kawachi H, Shimizu F & Inagami T (2006b). Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 17, 2495 2503.
12. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T & Hayashi M (2006c). Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47, 894 900.
13. Lee MH, Song HK, Ko GJ, Kang YS, Han SY, Han KH, Kim HK, Han JY & Cha DR (2008). Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 74, 890 900.
14. Le Lay S, Krief S, Farnier C, Lefrere I, Le Liepvre X, Bazin R, Ferre P & Dugail I (2001). Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J Biol Chem 276, 16904 16910.
15. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM & Snapinn S (2002). Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20, 1879 1886.
16. Lowell BB & Spiegelman BM (2000). Towards a molecular understanding of adaptive thermogenesis. Nature 404, 652 660.
17. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y & Nishiyama A (2005). Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 16, 703 711.
18. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T & Sraer JD (2002). Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109, 1417 1427.
19. Reaven GM (1991). Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 90, 7S 12S.
20. Saltiel AR (2001). You are what you secrete. Nat Med 7, 887 888.
21. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y & Ishida S (2009). (Pro)renin receptor-mediated transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes (in press); DOI : 10.2337/db08-0254.
22. Shan Z, Cuadra AE, Sumners C & Raizada MK (2008). Characterization of a functional (pro)renin receptor in rat brain neurons. Exp Physiol 93, 701 708.
23. Skurk T, Alberti-Huber C, Herder C & Hauner H (2007). Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92, 1023 1033.
24. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, Ishida Y, Nakamura Y & Murakami K (2003). Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 278, 22217 22222.
25. Takada M, Ura N, Higashiura K, Murakami H, Togashi N & Shimamoto K (2001). Effects of cilnidipine on muscle fiber composition, capillary density and muscle blood flow in fructose-fed rats. Hypertens Res 24, 565 572.
26. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA & Sowers JR (2008). Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol 294, R673 R680.
27. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH & Zinman B (2001). Ramipril and the development of diabetes. JAMA 286, 1882 1885.